Latest news with #SilenceTherapeutics
Yahoo
16-05-2025
- Business
- Yahoo
Spotlight On Silence Therapeutics And 2 Other Promising Penny Stocks
Over the last 7 days, the United States market has risen by 4.5%, contributing to an overall increase of 11% over the past year, with earnings forecasted to grow annually by 14%. For investors looking beyond well-known names, penny stocks—often smaller or newer companies—can present surprising opportunities. Despite being a somewhat outdated term, these stocks remain relevant as they can offer both value and growth potential when backed by strong financials and a clear growth path. Name Share Price Market Cap Financial Health Rating Safe Bulkers (NYSE:SB) $3.71 $384.78M ★★★★☆☆ Perfect (NYSE:PERF) $1.81 $186.38M ★★★★★★ WM Technology (NasdaqGS:MAPS) $1.175 $198.45M ★★★★★★ Flexible Solutions International (NYSEAM:FSI) $4.31 $54.76M ★★★★★★ Imperial Petroleum (NasdaqCM:IMPP) $2.56 $88.45M ★★★★★★ Table Trac (OTCPK:TBTC) $4.50 $20.83M ★★★★★★ BAB (OTCPK:BABB) $0.82 $5.85M ★★★★★★ Lifetime Brands (NasdaqGS:LCUT) $3.33 $75.76M ★★★★★☆ New Horizon Aircraft (NasdaqCM:HOVR) $0.589 $14.59M ★★★★★★ CBAK Energy Technology (NasdaqCM:CBAT) $0.876 $80.18M ★★★★★☆ Click here to see the full list of 741 stocks from our US Penny Stocks screener. Let's dive into some prime choices out of the screener. Simply Wall St Financial Health Rating: ★★★★★★ Overview: Silence Therapeutics plc is a biotechnology company focused on developing siRNA-based therapies to target gene expression in hematology, cardiovascular, and rare diseases, with a market cap of $191.73 million. Operations: Silence Therapeutics has not reported any specific revenue segments. Market Cap: $191.73M Silence Therapeutics, a pre-revenue biotech firm with a market cap of $191.73 million, has experienced significant financial volatility. Recent earnings revealed a sharp decline in sales to US$0.142 million for Q1 2025 from US$15.7 million the previous year, alongside an increased net loss of US$28.53 million. Despite being debt-free and having sufficient cash runway for over a year, the company faces challenges due to its unprofitability and volatile share price. Management changes include Tim McInerney joining as director and chair of the Remuneration Committee, potentially influencing future strategic decisions amid ongoing product development efforts. Dive into the specifics of Silence Therapeutics here with our thorough balance sheet health report. Learn about Silence Therapeutics' future growth trajectory here. Simply Wall St Financial Health Rating: ★★★★★★ Overview: Cabaletta Bio, Inc. is a clinical-stage biotechnology company dedicated to developing engineered T cell therapies for autoimmune diseases, with a market cap of $91.85 million. Operations: Cabaletta Bio, Inc. currently does not report any revenue segments as it is focused on developing engineered T cell therapies for autoimmune diseases. Market Cap: $91.85M Cabaletta Bio, with a market cap of US$91.85 million, is a pre-revenue biotech company focused on engineered T cell therapies for autoimmune diseases. Despite its unprofitability and increasing net losses (US$35.94 million in Q1 2025), it remains debt-free with sufficient cash runway for over a year. Recent FDA support for its rese-cel therapy and RMAT designation could expedite development, though risks remain due to volatile market conditions and trial uncertainties. Upcoming clinical data presentations at the EULAR 2025 Congress may provide further insights into its therapeutic potential amidst ongoing strategic developments like share authorization increases. Take a closer look at Cabaletta Bio's potential here in our financial health report. Evaluate Cabaletta Bio's prospects by accessing our earnings growth report. Simply Wall St Financial Health Rating: ★★★★★★ Overview: Magnachip Semiconductor Corporation designs, manufactures, and supplies analog and mixed-signal semiconductor solutions for various applications including communications, IoT, consumer electronics, computing, industrial, and automotive sectors with a market cap of approximately $134.62 million. Operations: The company's revenue is primarily derived from its Standard Products Business, with $166.80 million coming from Power Analog Solutions and $54.34 million from Mixed Signal Solutions, alongside $10.60 million generated by Transitional Fab 3 Foundry Services. Market Cap: $134.62M Magnachip Semiconductor, with a market cap of US$134.62 million, is navigating its transition to a pure-play Power company by exiting the Display business to focus on Power Analog Solutions and Mixed Signal Solutions. The company has provided consolidated earnings guidance for Q2 2025, expecting revenue between US$45 million and US$49 million. Despite being unprofitable with increasing net losses, Magnachip's strategic shift aims at achieving profitability by 2026 through improved operational focus and product innovation like its new Gen6 IGBTs for solar inverters. The company's strong cash position exceeds its debt obligations, providing financial stability during this restructuring phase. Unlock comprehensive insights into our analysis of Magnachip Semiconductor stock in this financial health report. Gain insights into Magnachip Semiconductor's future direction by reviewing our growth report. Navigate through the entire inventory of 741 US Penny Stocks here. Ready For A Different Approach? Uncover 17 companies that survived and thrived after COVID and have the right ingredients to survive Trump's tariffs. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include NasdaqGM:SLN NasdaqGS:CABA and NYSE:MX. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Error while retrieving data Sign in to access your portfolio Error while retrieving data
Business Insider
09-05-2025
- Business
- Business Insider
Analysts Offer Insights on Healthcare Companies: Definitive Healthcare Corp (DH) and Silence Therapeutics (SLN)
There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Definitive Healthcare Corp (DH – Research Report) and Silence Therapeutics (SLN – Research Report) with bullish sentiments. Protect Your Portfolio Against Market Uncertainty Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter. Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox. Definitive Healthcare Corp (DH) In a report released today, Ryan Daniels from William Blair maintained a Buy rating on Definitive Healthcare Corp. The company's shares closed last Thursday at $2.81, close to its 52-week low of $2.55. According to Daniels is a 4-star analyst with an average return of 7.7% and a 49.6% success rate. Daniels covers the Healthcare sector, focusing on stocks such as Lifestance Health Group, Pediatrix Medical Group, and Alignment Healthcare. The word on The Street in general, suggests a Hold analyst consensus rating for Definitive Healthcare Corp with a $4.57 average price target. Silence Therapeutics (SLN) William Blair analyst Myles Minter maintained a Buy rating on Silence Therapeutics today. The company's shares closed last Thursday at $3.56, close to its 52-week low of $3.19. According to Minter is a 4-star analyst with an average return of 5.0% and a 48.6% success rate. Minter covers the Healthcare sector, focusing on stocks such as CAMP4 Therapeutics Corporation, Neumora Therapeutics, Inc., and Entrada Therapeutics Inc.
Yahoo
06-03-2025
- Business
- Yahoo
Revenue Downgrade: Here's What Analysts Forecast For Silence Therapeutics plc (NASDAQ:SLN)
Today is shaping up negative for Silence Therapeutics plc (NASDAQ:SLN) shareholders, with the analysts delivering a substantial negative revision to this year's forecasts. There was a fairly draconian cut to their revenue estimates, perhaps an implicit admission that previous forecasts were much too optimistic. After the downgrade, the consensus from Silence Therapeutics' six analysts is for revenues of UK£15m in 2025, which would reflect a painful 65% decline in sales compared to the last year of performance. Prior to the latest estimates, the analysts were forecasting revenues of UK£25m in 2025. It looks like forecasts have become a fair bit less optimistic on Silence Therapeutics, given the sizeable cut to revenue estimates. View our latest analysis for Silence Therapeutics Notably, the analysts have cut their price target 15% to US$39.65, suggesting concerns around Silence Therapeutics' valuation. Another way we can view these estimates is in the context of the bigger picture, such as how the forecasts stack up against past performance, and whether forecasts are more or less bullish relative to other companies in the industry. These estimates imply that sales are expected to slow, with a forecast annualised revenue decline of 65% by the end of 2025. This indicates a significant reduction from annual growth of 40% over the last five years. Compare this with our data, which suggests that other companies in the same industry are, in aggregate, expected to see their revenue grow 20% per year. So although its revenues are forecast to shrink, this cloud does not come with a silver lining - Silence Therapeutics is expected to lag the wider industry. The most important thing to take away is that analysts cut their revenue estimates for this year. They also expect company revenue to perform worse than the wider market. Furthermore, there was a cut to the price target, suggesting that the latest news has led to more pessimism about the intrinsic value of the business. Often, one downgrade can set off a daisy-chain of cuts, especially if an industry is in decline. So we wouldn't be surprised if the market became a lot more cautious on Silence Therapeutics after today. Thirsting for more data? At least one of Silence Therapeutics' six analysts has provided estimates out to 2027, which can be seen for free on our platform here. Of course, seeing company management invest large sums of money in a stock can be just as useful as knowing whether analysts are downgrading their estimates. So you may also wish to search this free list of stocks with high insider ownership. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Yahoo
05-03-2025
- Business
- Yahoo
Silence Therapeutics to Webcast Presentation at the Leerink Partners Global Healthcare Conference
LONDON, March 05, 2025--(BUSINESS WIRE)--Silence Therapeutics plc, Nasdaq: SLN ("Silence" or the "Company"), a global clinical-stage company developing novel siRNA (short interfering RNA) therapies, today announced that management will present a company overview at the Leerink Partners Global Healthcare Conference on Wednesday, March 12th at 1:00 p.m. ET. The live webcast can be accessed via the Investors section of the Silence website at An archived replay of the webcast will be available following the conference. About Silence Therapeutics Silence Therapeutics is a global clinical-stage biotechnology company committed to transforming people's lives by silencing diseases through precision engineered medicines created with proprietary siRNA (short interfering RNA) technology. Silence leverages its mRNAi GOLD™ platform to create innovative siRNAs designed to precisely target and silence disease-associated genes in the liver, which represents a substantial opportunity. Silence focuses on areas of high unmet medical need with programs advancing in cardiovascular disease, hematology and rare diseases. For more information, please visit View source version on Contacts Inquiries:Silence Therapeutics plc Gem Hopkins, VP, Head of IR and Corporate Communicationsir@ Tel: +1 (646) 637-3208 Sign in to access your portfolio
